Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Earnings Data
Report Date
Nov 06, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call was largely positive, with strong revenue growth driven by both Vafseo and Auryxia, significant advancements in clinical trials, and an overall solid financial position. While there were some challenges with adherence rates and potential future competition for Auryxia, the positive aspects and future prospects significantly outweighed the negative points.Company Guidance
Strong Revenue Growth
The company reported $62.5 million in total revenues for Q2 2025, up from $43.6 million in Q2 2024, marking an increase of $18.9 million. Net product revenues increased to $60.5 million from $41.2 million in the previous year.
Successful Launch of Vafseo
Vafseo generated over $13 million in revenue in Q2 2025, a 55% increase over Q1 2025. Prescribing access is expected to increase significantly, with access to over 275,000 dialysis patients anticipated in Q4 2025.
Auryxia Sales Growth
Auryxia sales increased to $47.2 million in Q2 2025 from $41.2 million in Q2 2024, despite losing IP exclusivity in March.
Positive Financial Position
The company ended Q2 2025 with $137.3 million in cash and cash equivalents and reported a net income of $247,000 compared to a net loss of $8.6 million in Q2 2024.
Expansion of Patient Access
The company reported that DaVita, a major dialysis provider, is expected to significantly increase patient access to Vafseo, with an operational pilot to conclude in Q4 2025.
Progress in Clinical Trials
The VOICE trial was fully enrolled with over 2,100 patients, and the VOCAL study in 18 DaVita dialysis facilities was initiated.
AKBA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AKBA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $3.78 | $3.01 | -20.37% |
May 08, 2025 | $2.46 | $2.62 | +6.50% |
Mar 13, 2025 | $1.93 | $1.69 | -12.44% |
Nov 07, 2024 | $2.00 | $1.86 | -7.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Akebia Therapeutics (AKBA) report earnings?
Akebia Therapeutics (AKBA) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).
What is Akebia Therapeutics (AKBA) earnings time?
Akebia Therapeutics (AKBA) earnings time is at Nov 06, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBA EPS forecast?
AKBA EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.